Advertisement

World Journal of Pediatrics

, Volume 12, Issue 1, pp 8–18 | Cite as

Prematurity and the burden of influenza and respiratory syncytial virus disease

  • Bernhard ReschEmail author
  • Stefan Kurath-Koller
  • Monika Eibisberger
  • Werner Zenz
Review article

Abstract

Background

Respiratory morbidity of former preterm infants and especially those with bronchopulmonary dysplasia (BPD) is high during infancy and early childhood.

Data sources

We performed a review based on a literature search including EMBASE, MEDLINE, and CINAHL databases to identify all relevant papers published in the English and German literature on influenza and respiratory syncytial virus infection associated with preterm infant, prematurity, and BPD between 1980 and 2014.

Results

Recurrent respiratory symptoms remain common at preschool age, school age and even into young adulthood. Acute viral respiratory tract infections due to different pathogens cause significant morbidity and necessitate rehospitalizations during the first years of life. Influenza virus infection plays a minor role compared to respiratory syncytial virus (RSV) associated respiratory tract infection during infancy and early childhood. Nevertheless, particular morbidity to both viruses is high.

Conclusions

The particular burden of both viral diseases in preterm infants is dominated by RSV and its associated rehospitalizations during the first two years of life. Prophylactic measures include vaccination against influenza virus of family members and caregivers and active immunization starting at the age of 6 months, and monthly injections of palivizumab during the cold season to avoid severe RSV disease and its sequelae.

Key words

bronchopulmonary dysplasia influenza preterm infant respiratory infectious disease respiratory syncytial virus 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Doyle LW, Anderson PJ. Pulmonary and neurological follow-up of extremely preterm infants. Neonatology 2010;97:388–394.PubMedCrossRefGoogle Scholar
  2. 2.
    Resch B, Pasnocht A, Gusenleitner W, Müller W. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29–36 weeks gestational age. J Infect 2005;50:397–403.PubMedCrossRefGoogle Scholar
  3. 3.
    Greenough A. Long-term respiratory consequences of premature birth at less than 32 weeks of gestation. Early Hum Dev 2013;89 Suppl 2:S25–S27.PubMedCrossRefGoogle Scholar
  4. 4.
    Peacock JL, Lo JW, D’ Costa W, Calvert S, Marlow N, Greenough A. Respiratory morbidity at follow-up of small-for-gestational-age infants born very prematurely. Pediatr Res 2013;73:457–463.PubMedCrossRefGoogle Scholar
  5. 5.
    El Mazloum D, Moschino L, Bozzetto S, Baraldi E. Chronic lung disease of prematurity: long-term respiratory outcome. Neonatology 2014;105:352–356.PubMedCrossRefGoogle Scholar
  6. 6.
    Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007;357:1946–1955.PubMedCrossRefGoogle Scholar
  7. 7.
    Bhandari A, Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics 2009;123:1562–1573.PubMedCrossRefGoogle Scholar
  8. 8.
    Joshi S, Wilson DG, Kotecha S, Pickerd N, Fraser AG, Kotecha S. Cardiovascular function in children who had chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2014;99:F373–F379.PubMedCrossRefGoogle Scholar
  9. 9.
    Filippone M, Bonetto G, Cherubin E, Carraro S, Baraldi E. Childhood course of lung function in survivors of bronchopulmonary dysplasia. JAMA 2009;302:1418–1420.PubMedCrossRefGoogle Scholar
  10. 10.
    Mitchell SH, Teague WG, Reduced gas transfer at rest and during exercise in school-age survivors of bronchopulmonary dysplasia. Am J Respir Crit Care Med 1998;157:1406–1412.PubMedCrossRefGoogle Scholar
  11. 11.
    Been JV, Lugtenberg MJ, Smets E, van Schayck CP, Kramer BW, Mommers M, et al. Preterm birth and childhood wheezing disorders: a systematic review and meta-analysis. PLoS Med 2014;11:e1001596.Google Scholar
  12. 12.
    Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR, Weinberg GA, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004;113:1758–1764.PubMedCrossRefGoogle Scholar
  13. 13.
    Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225–231.PubMedCrossRefGoogle Scholar
  14. 14.
    Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 1999;282:1440–1446.PubMedCrossRefGoogle Scholar
  15. 15.
    Gouyon JB, Rozé JC, Guillermet-Fromentin C, Glorieux I, Adamon L, DI Maio M, et al. Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study. Epidemiol Infect 2013;141:816–826.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137:865–870.PubMedCrossRefGoogle Scholar
  17. 17.
    Colin AA, McEvoy C, Castile RG. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks’ gestational age. Pediatrics 2010;126:115–128.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Vrijlandt EJ, Kerstjens JM, Duiverman EJ, Bos AF, Reijneveld SA. Moderately preterm children have more respiratory problems during their first 5 years of life than children born full term. Am J Respir Crit Care Med 2013;187:1234–1240.PubMedCrossRefGoogle Scholar
  19. 19.
    Resch B, Paes B. Are late preterm infants as susceptible to RSV infection as full term infants? Early Hum Dev 2011;87 Suppl 1:S47–S49.PubMedCrossRefGoogle Scholar
  20. 20.
    Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013;132:e341–e348.PubMedCrossRefGoogle Scholar
  21. 21.
    Paramore LC, Mahadevia PJ, Piedra PA. Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations. Pediatr Pulmonol 2010;45:578–584.PubMedGoogle Scholar
  22. 22.
    Fauroux B, Gouyon JB, Roze JC, Guillermet-Fromentin C, Glorieux I, Adamon L, et al. Respiratory morbidity of preterm infants of less than 33 weeks gestation without bronchopulmonary dysplasia: a 12-month follow-up of the CASTOR study cohort. Epidemiol Infect 2014;142:1362–1374.PubMedCrossRefGoogle Scholar
  23. 23.
    Pramana IA, Latzin P, Schlapbach LJ, Hafen G, Kuehni CE, Nelle M, et al. Respiratory symptoms in preterm infants: burden of disease in the first year of life. Eur J Med Res 2011;16:223–230.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol 2014;100:145–157.PubMedCrossRefGoogle Scholar
  25. 25.
    Resch B, Kurath S, Manzoni P. Epidemiology of respiratory syncytial virus infection in preterm infants. Open Microbiol J 2011;5:135–143.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Gross SJ, Iannuzzi DM, Kveselis DA, Anbar RD. Effect of preterm birth on pulmonary function at school age: a prospective controlled study. J Pediatr 1998;133:188–192.PubMedCrossRefGoogle Scholar
  27. 27.
    Hennessy EM, Bracewell MA, Wood N, Wolke D, Costeloe K, Gibson A, et al. Respiratory health in pre-school and school age children following extremely preterm birth. Arch Dis Child 2008;93:1037–1043.PubMedCrossRefGoogle Scholar
  28. 28.
    Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks’ gestation. Pediatrics 1991;88:527–532.PubMedGoogle Scholar
  29. 29.
    Pezzotti P, Mantovani J, Benincori N, Mucchino E, Di Lallo D. Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy. BMC Pediatr 2009;9:56.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Ralser E, Mueller W, Haberland C, Fink FM, Gutenberger KH, Strobl R, et al. Rehospitalization in the first 2 years of life in children born preterm. Acta Paediatr 2012;101:e1–e5.PubMedCrossRefGoogle Scholar
  31. 31.
    Berger TMI, Aebi C, Duppenthaler A, Stocker M, Swiss Pediatric Surveillance Unit. Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001–2005). Infection 2009;37:109–116.PubMedCrossRefGoogle Scholar
  32. 32.
    Vom Hove M, Prenzel F, Uhlig HH, Robel-Tillig E. Pulmonary outcome in former preterm, very low birth weight children with bronchopulmonary dysplasia: a case-control follow-up at school age. J Pediatr 2014;164:40–45.PubMedCrossRefGoogle Scholar
  33. 33.
    Fawke J, Lum S, Kirkby J, Hennessy E, Marlow N, Rowell V, et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med 2010;182:237–245.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Gross SJ, Iannuzzi DM, Kveselis DA, Anbar RD. Effect of preterm birth on pulmonary function at school age: a prospective controlled study. J Pediatr 1998;133:188–192.PubMedCrossRefGoogle Scholar
  35. 35.
    Broström EB, Thunqvist P, Adenfelt G, Borling E, Katz-Salamon M. Obstructive lung disease in children with mild to severe BPD. Respir Med 2010;104:362–370.PubMedCrossRefGoogle Scholar
  36. 36.
    Goyal NK, Fiks AG, Lorch SA. Association of late-preterm birth with asthma in young children: practice-based study. Pediatrics 2011;128:e830–e838.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Escobar GJ, Ragins A, Li SX, Prager L, Masaquel AS, Kipnis P. Recurrent wheezing in the third year of life among children born at 32 weeks’ gestation or later: relationship to laboratoryconfirmed, medically attended infection with respiratory syncytial virus during the first year of life. Arch Pediatr Adolesc Med 2010;164:915–922.PubMedCrossRefGoogle Scholar
  38. 38.
    Pelkonen AS, Hakulinen AL, Turpeinen M. Bronchial lability and responsiveness in school children born very preterm. Am J Respir Crit Care Med 1997;156:1178–1184.PubMedCrossRefGoogle Scholar
  39. 39.
    Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM. Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics 2006;118:108–113.PubMedCrossRefGoogle Scholar
  40. 40.
    Halvorsen T, Skadberg BT, Eide GE, Røksund OD, Carlsen KH, Bakke P. Pulmonary outcome in adolescents of extreme preterm birth: a regional cohort study. Acta Paediatr 2004;93:1294–1300.PubMedCrossRefGoogle Scholar
  41. 41.
    Kotecha SJ, Watkins WJ, Paranjothy S, Dunstan FD, Henderson AJ, Kotecha S. Effect of late preterm birth on longitudinal lung spirometry in school age children and adolescents. Thorax 2012;67:54–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Kaplan E, Bar-Yishay E, Prais D, Klinger G, Mei-Zahav M, Mussaffi H, et al. Encouraging pulmonary outcome for surviving, neurologically intact, extremely premature infants in the postsurfactant era. Chest 2012;142:725–733.PubMedCrossRefGoogle Scholar
  43. 43.
    Guimarães H, Rocha G, Pissarra S, Guedes MB, Nunes T, Vitor B. Respiratory outcomes and atopy in school-age children who were preterm at birth, with and without bronchopulmonary dysplasia. Clinics (Sao Paulo) 2011;66:425–430.CrossRefGoogle Scholar
  44. 44.
    Konefal H, Czeszynska MB, Merritt TA. School-age spirometry in survivors of chronic lung disease of prematurity in the surfactant era. Ginekol Pol 2013;84:286–292.PubMedCrossRefGoogle Scholar
  45. 45.
    Welsh L, Kirkby J, Lum S, Odendaal D, Marlow N, Derrick G, et al. The EPICure study: maximal exercise and physical activity in school children born extremely preterm. Thorax 2010;65:165–172.PubMedCrossRefGoogle Scholar
  46. 46.
    Teo SS, Nguyen-Van-Tam JS, Booy R. Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps? Arch Dis Child 2005;90:532–536.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827–835.PubMedCrossRefGoogle Scholar
  48. 48.
    Reid A. The effects of the 1918–1919 influenza pandemic on infant and child health in Derbyshire. Med Hist 2005;49:29–54.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Iskander M, Kesson A, Dwyer D, Rost L, Pym M, Wang H, et al. The burden of influenza in children under 5 years admitted to the Children’s Hospital at Westmead in the winter of 2006. J Paediatr Child Health 2009;45:698–703.PubMedCrossRefGoogle Scholar
  50. 50.
    Munoz FM. Influenza virus infection in infancy and early childhood. Paediatr Respir Rev 2003;4:99–104.PubMedCrossRefGoogle Scholar
  51. 51.
    Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr Infect Dis J 1997;16:1065–1068.PubMedCrossRefGoogle Scholar
  52. 52.
    Kao HT, Huang YC, Lin TY. Influenza A virus infection in infants. J Microbiol Immunol Infect 2000;33:105–108.PubMedGoogle Scholar
  53. 53.
    Bauer CR, Elie K, Spence L, Stern L. Hong Kong influenza in a neonatal unit. JAMA 1973;223:1233–1235.PubMedCrossRefGoogle Scholar
  54. 54.
    Sagrera X, Ginovart G, Raspall F, Rabella N, Sala P, Sierra M, et al. Outbreaks of influenza A virus infection in neonatal intensive care units. Pediatr Infect Dis J 2002;21:196–200.PubMedCrossRefGoogle Scholar
  55. 55.
    Cunney RJ, Bialachowski A, Thornley D, Smaill FM, Pennie RA. An outbreak of influenza A in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2000;21:449–454.PubMedCrossRefGoogle Scholar
  56. 56.
    Munoz FM, Campbell JR, Atmar RL, Garcia-Prats J, Baxter BD, Johnson LE, et al. Influenza A virus outbreak in a neonatal intensive care unit. Pediatr Infect Dis J 1999;18:811–815.PubMedCrossRefGoogle Scholar
  57. 57.
    Dagan R, Hall CB. Influenza A virus infection imitating bacterial sepsis in early infancy. Pediatr Infect Dis 1984;3:218–221.PubMedCrossRefGoogle Scholar
  58. 58.
    Puck JM, Glezen WP, Frank AL, Six HR. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. J Infect Dis 1980;142:844–849.PubMedCrossRefGoogle Scholar
  59. 59.
    Yen CJ, Louie JK, Schechter R. Infants hospitalized in intensive care units with 2009 H1N1 influenza infection, California, 2009–2010. Pediatr Infect Dis J 2012;31:e52–e55.PubMedCrossRefGoogle Scholar
  60. 60.
    van den Dungen FA, van Furth AM, Fetter WP, Zaaijer HL, van Elburg RM. Fatal case of influenza B virus pneumonia in a preterm neonate. Pediatr Infect Dis J 2001;20:82–84.PubMedCrossRefGoogle Scholar
  61. 61.
    Chaves SS, Perez A, Farley MM, Miller L, Schaffner W, Lindegren ML, et al. The burden of influenza hospitalizations in infants from 2003 to 2012, United States. Pediatr Infect Dis J 2014;33:912–919.PubMedCrossRefGoogle Scholar
  62. 62.
    Drysdale SB, Alcazar M, Wilson T, Smith M, Zuckerman M, Wedderburn CJ, et al. Pandemic influenza A (H1N1) virus 2009 in a prospectively followed cohort of prematurely born infants. Pediatr Infect Dis J 2012;31:91–92.PubMedCrossRefGoogle Scholar
  63. 63.
    Kinney JS, Robertsen CM, Johnson KM, Gaddis M, Wheeler R, Jackson MA, et al. Seasonal respiratory viral infections. Impact on infants with chronic lung disease following discharge from the neonatal intensive care unit. Arch Pediatr Adolesc Med 1995;149:81–85.PubMedCrossRefGoogle Scholar
  64. 64.
    Resch B, Eibisberger M, Morris N, Müller W. Respiratory syncytial virus-and influenza virus-associated hospitalizations in infants less than 12 months of age. Pediatr Infect Dis J 2011;30:797–799.PubMedCrossRefGoogle Scholar
  65. 65.
    Jurgens HA, Amancherla K, Johnson RW. Influenza infection induces neuroinflammation, alters hippocampal neuron morphology, and impairs cognition in adult mice. J Neurosci 2012;32:3958–3968.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Jang H, Boltz D, McClaren J, Pani AK, Smeyne M, Korff A, et al. Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice. J Neurosci 2012;32:1545–1559.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Studahl M. Influenza virus and CNS manifestations. J Clin Virol 2003;28:225–232.PubMedCrossRefGoogle Scholar
  68. 68.
    Yoshikawa H, Yamazaki S, Watanabe T, Abe T. Study of influenza-associated encephalitis/encephalopathy in children during the 1997 to 2001influenza seasons. J Child Neurol 2001;16:885–890.PubMedCrossRefGoogle Scholar
  69. 69.
    Pannaraj PS, Tam B, Akan D. Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak. J Perinatol 2011;31:487–493.PubMedCrossRefGoogle Scholar
  70. 70.
    Tsagris V, Nika A, Kyriakou D, Kapetanakis I, Harahousou E, Stripeli F, et al Influenza A/H1N1/2009 outbreak in a neonatal intensive care unit. J Hosp Infect 2012;81:36–40.PubMedCrossRefGoogle Scholar
  71. 71.
    Acosta EP, Jester P, Gal P, Wimmer J, Wade J, Whitley RJ, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis 2010;202:563–566.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Holgate SL, Bekker A, Rabie H, Cotton MF. Oseltamivir use in low-birth weight infants during the 2009 nH1N1 influenza a outbreak in the Western Cape, South Africa. J Trop Pediatr 2012;58:102–106.PubMedCrossRefGoogle Scholar
  73. 73.
    Nordin JD, Kharbanda EO, Vazquez Benitez G, Lipkind H, Vellozzi C, Destefano F, et al. Maternal influenza vaccine and risks for preterm or small for gestational age birth. J Pediatr 2014;164:1051–1057.PubMedCrossRefGoogle Scholar
  74. 74.
    Chavant F, Ingrand I, Jonville-Bera AP, Plazanet C, Gras-Champel V, Lagarce L, et al. The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza. Drug Saf 2013;36:455–465.PubMedCrossRefGoogle Scholar
  75. 75.
    Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 2012;308:165–174.PubMedCrossRefGoogle Scholar
  76. 76.
    Shen S, Campitelli MA, Calzavara A, Guttmann A, Kwong JC. Seasonal influenza vaccine effectiveness in pre-and fullterm children aged 6–23 months over multiple seasons. Vaccine 2013;31:2974–2978.PubMedCrossRefGoogle Scholar
  77. 77.
    Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917–1928.PubMedCrossRefGoogle Scholar
  78. 78.
    Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543–546.PubMedGoogle Scholar
  79. 79.
    Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847–852.PubMedCrossRefGoogle Scholar
  80. 80.
    Arnold SR, Wang EE, Law BJ, Boucher FD, Stephens D, Robinson JL, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 1999;18:866–869.PubMedGoogle Scholar
  81. 81.
    Wilkesmann A, Ammann RA, Schildgen O, Eis-Hübinger AM, Müller A, Seidenberg J, et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 2007;26:485–491.PubMedCrossRefGoogle Scholar
  82. 82.
    Garenne M, Ronsmans C, Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q 1992;45:180–191.PubMedGoogle Scholar
  83. 83.
    Hall CB, Walsh EE, Schnabel KC, Long CE, McConnochie KM, Hildreth SW, et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990;162:1283–1290.PubMedCrossRefGoogle Scholar
  84. 84.
    Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev 2000;13:1–15.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Resch B, Gusenleitner W, Müller W. The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection 2002;30:193–197.PubMedCrossRefGoogle Scholar
  86. 86.
    Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, et al. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:230–236.PubMedGoogle Scholar
  87. 87.
    Resch B, Gusenleitner W, Müller WD, Haas J. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur J Clin Microbiol Infect Dis 2006;25:120–122.PubMedCrossRefGoogle Scholar
  88. 88.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000;154:55–61.PubMedGoogle Scholar
  89. 89.
    McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol 2002;34:262–266.PubMedCrossRefGoogle Scholar
  90. 90.
    Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000;19:592–597.CrossRefGoogle Scholar
  91. 91.
    McIntosh K. Respiratory syncytial virus infections in infants and children: diagnosis and treatment. Pediatr Rev 1987;9:191–196.PubMedCrossRefGoogle Scholar
  92. 92.
    Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. Philadelphia: Saunders, 1998: 2084–2111.Google Scholar
  93. 93.
    Kristensen K, Dahm T, Frederiksen PS, Ibsen J, Iyore E, Jensen AM. Epidemiology of respiratory syncytial virus infection requiring hospitalization in East Denmark. Pediatr Infect Dis J 1998;17:996–1000.PubMedCrossRefGoogle Scholar
  94. 94.
    Resch B, Gusenleitner W, Mandl C, Müller W. Epidemiology of respiratory syncytial virus infection in Southern Austria. Pediatr Infect Dis J 2000;19:587–588.PubMedCrossRefGoogle Scholar
  95. 95.
    Wert SE. Normal and abnormal structural development of the lung. In: Polin RA, Fox WW, Abmann SH, eds. Fetal and neonatal physiology. Philadelphia: Saunders, 2004: 784–794.Google Scholar
  96. 96.
    Ballow M, Cates KL, Rowe JC, Goetz C, Desbonnet C. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986;20:899–904.PubMedCrossRefGoogle Scholar
  97. 97.
    Meert K, Heidemann S, Abella B, Sarnaik A. Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med 1990;18:1357–1359.PubMedCrossRefGoogle Scholar
  98. 98.
    Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999;104:894–899.PubMedCrossRefGoogle Scholar
  99. 99.
    Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed 2005;90:F64–F68.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001;20:874–879.PubMedCrossRefGoogle Scholar
  101. 101.
    Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806–814.PubMedCrossRefGoogle Scholar
  102. 102.
    Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27:788–793.PubMedCrossRefGoogle Scholar
  103. 103.
    Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199–203.PubMedGoogle Scholar
  104. 104.
    Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997;99:93–99.CrossRefGoogle Scholar
  105. 105.
    Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102:531–537.CrossRefGoogle Scholar
  106. 106.
    Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child 2000;83:122–127.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85:463–468.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Flamant C, Hallalel F, Nolent P, Chevalier JY, Renolleau S. Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation. Eur J Pediatr 2005;164:93–98.PubMedCrossRefGoogle Scholar
  109. 109.
    Park A, Suh SI, Son GR, Lee YH, Seo HS, Eun BL, et al. Respiratory syncytial virus-related encephalitis: magnetic resonance imaging findings with diffusion-weighted study. Neuroradiology 2014;56:163–168.PubMedCrossRefGoogle Scholar
  110. 110.
    Espinoza JA, Bohmwald K, Céspedes PF, Gómez RS, Riquelme SA, Cortés CM, et al. Impaired learning resulting from respiratory syncytial virus infection. Proc Natl Acad Sci U S A 2013;110:9112–9117.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Ricart S, Rovira N, Garcia-Garcia JJ, Pumarola T, Pons M, Muñoz-Almagro C, et al. Frequency of apnea and respiratory viruses in infants with bronchiolitis. Pediatr Infect Dis J 2014;33:988–990.PubMedCrossRefGoogle Scholar
  112. 112.
    Erez DL, Yarden-Bilavsky H, Mendelson E, Yuhas Y, Ashkenazi S, Nahum E, et al. Apnea induced by respiratory syncytial virus infection is not associated with viral invasion of the central nervous system. Pediatr Infect Dis J 2014;33:880–881.PubMedCrossRefGoogle Scholar
  113. 113.
    Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newbornsand infants. Ital J Pediatr 2014;40:65.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Ventre K, Randolph A. Withdrawn: ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2010;(5):CD000181.Google Scholar
  115. 115.
    Rodriguez WJ. Therapy of RSV. In: Weisman LE, Groothuis JR, eds. Contemporary diagnosis and management of respiratory syncytial virus. Pennsylvania: Handbooks in Health Care, 2000: 136–152.Google Scholar
  116. 116.
    Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532–540.PubMedCrossRefGoogle Scholar
  117. 117.
    Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998;17:110–115.CrossRefGoogle Scholar
  118. 118.
    Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013;368:1791–1799.PubMedCrossRefGoogle Scholar
  119. 119.
    Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010;125:e35–e51.PubMedCrossRefGoogle Scholar
  120. 120.
    Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 2011;70:186–191.PubMedCrossRefGoogle Scholar
  121. 121.
    Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1694–1701.CrossRefGoogle Scholar
  122. 122.
    Weiner LB, Masaquel AS, Polak MJ, Mahadevia PJ. Costeffectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. J Med Econ 2012;15:997–1018.PubMedCrossRefGoogle Scholar
  123. 123.
    Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ 2012;15:987–996.PubMedCrossRefGoogle Scholar
  124. 124.
    Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling ofsubgroup analyses. Health Technol Assess 2011;15:iii-iv, 1–124.CrossRefGoogle Scholar
  125. 125.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013;(4):CD006602.Google Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Bernhard Resch
    • 1
    Email author
  • Stefan Kurath-Koller
    • 2
  • Monika Eibisberger
    • 2
  • Werner Zenz
    • 3
  1. 1.Research Unit for Neonatal Infectious Diseases and Epidemiology, Division of Neonatology, Department of Pediatrics and Adolescent MedicineMedical University of GrazGrazAustria
  2. 2.Research Unit for Neonatal Infectious Diseases and EpidemiologyMedical University of GrazGrazAustria
  3. 3.Research Unit for Infectious Diseases and Vaccinology, Division of General Pediatrics, Department of Pediatrics and Adolescent MedicineMedical University of GrazGrazAustria

Personalised recommendations